SCHEMBL6340922

SCHEMBL6340922

O=C(c1cccc([N+](=O)[O-])c1)N(CCO)CCO

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES2 O00748 1/20 0.58
CES1 P23141 1/20 0.58
TP53 P04637 1/20 0.57
ALDH1A1 P00352 7/20 0.55
TSHR P16473 3/20 0.55
LMNA P02545 2/20 0.51
KMO O15229 1/20 0.51
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
HTT P42858 2/20 0.49
HPGD P15428 2/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
MAPT P10636 1/20 0.49
RAB9A P51151 1/20 0.49
PRSS1 P07477 1/20 0.49
PRSS2 P07478 1/20 0.49
PRSS3 P35030 1/20 0.49
OPRM1 P35372 1/20 0.48
OPRD1 P41143 1/20 0.48
MAPK1 P28482 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24497003 0.84 ALDH1A1 (0.60) CES2CES1TP53ALDH1A1TSHR
SCHEMBL11570711 0.84 CYP3A4 (0.50) CES2CES1TP53ALDH1A1KMT2A
SCHEMBL11362571 0.83 OPRM1 (0.65) CES2CES1TP53ALDH1A1TSHR
SCHEMBL7747413 0.83 ALDH1A1 (0.54) CES2CES1TP53ALDH1A1TSHR
SCHEMBL9167379 0.82 ALDH1A1 (0.55) CES2CES1TP53ALDH1A1TSHR
SCHEMBL28476636 0.82 ALDH1A1 (0.55) CES2CES1TP53ALDH1A1TSHR
SCHEMBL11153531 0.81 TSHR (0.62) CES2CES1TP53ALDH1A1TSHR
SCHEMBL27616952 0.79 KMT2A (0.62) CES2CES1TP53ALDH1A1TSHR
SCHEMBL11730272 0.79 CES2 (0.55) CES2CES1TP53ALDH1A1TSHR
SCHEMBL30512072 0.79 CES2 (0.68) CES2CES1TP53ALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6858641-B2 Substituted indolinones BOEHRINGER INGELHEIM PHARMA KG (DE) 2005-02-22 US disclosed
EP-1379501-A1 INDOLINONES, SUBSTITUTED IN POSITION 6, AND THEIR USE AS KINASE INHIBITORS Boehringer Ingelheim Pharma GmbH & Co.KG (DE) 2004-01-14 EP disclosed
US-20030092756-A1 Substituted indolinones BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2003-05-15 US disclosed
WO-2002081445-A1 INDOLINONES, SUBSTITUTED IN POSITION 6, AND THEIR USE AS KINASE INHIBITORS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2002-10-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030092756-A1 Substituted indolinones CDK1, CDK2, CDKL1 CES2 3505/4885CES1 1964/4885TP53 1204/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.